Investors & Media

Announced global epigenetic regulation and capsid delivery license agreement with Genentech to develop novel genomic medicines for neurodegenerative diseases. Expect to receive $50 million in near-term upfront license fees and milestone payments and eligible to earn up to $1.9 billion in milestone

Agreement   leverages Sangamo’s proprietary capsid delivery platform and epigenetic regulation capabilities to address certain neurodegenerative diseases Sangamo expected to receive $50 million in near-term upfront license fees and milestone payments and is eligible to earn up to $1.9   billion in

RICHMOND, Calif. --(BUSINESS WIRE)--Jul. 30, 2024-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company has scheduled the release of its second quarter 2024 financial results after the market close on Tuesday, August 6, 2024 .

Giroctocogene fitelparvovec trial meets primary and key secondary objectives of superiority compared to prophylaxis RICHMOND, Calif. --(BUSINESS WIRE)--Jul. 24, 2024-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported on Pfizer Inc.’s announcement of positive